The Center for Biosimilars® recaps the top news for the week of November 5, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 5.
Number 5: Oncobiologics has announced that it has dosed the first patients with wet age-related macular degeneration in a clinical trial of ONS-5010, an ophthalmic bevacizumab candidate.
Number 4: Three attorneys from Goodwin hosted a webinar this week to provide updates on topics ranging from the Biologics Price Competition and Innovation Act Litigation, the Patent Trial and Appeal Board, and recent regulatory and FDA issues related to biosimilars.
Number 3: Regeneron posted positive third quarter earnings results for 2018 that show aflibercept sales in the United States increased 7 percent to 1.02 billion dollars versus third quarter 2017 results.
Number 2: Momenta Pharmaceuticals recently announced that it has reached a settlement with Humira-maker AbbVie over a proposed biosimilar adalimumab, M923.
Number 1: Sandoz announced this week that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013.
Finally, last week, our e-newsletter asked if the eventual approval of upadacitinib could curb the uptake of biosimilar infliximab.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.